Collectionner le produit
Détails du produit
FAB
- Comprehensive validation - Validated with various antibody drugs.
- Simple and fast operation - No complicated washing steps, significantly reducing time.
- High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
- Accurate and reliable results - High sensitivity with minimal matrix effects.
- High throughput capability - Support multiple product specifications, ideal for high-throughput screening.
- Fast completion - Results in just 1 hour.
Product Specifications
Assay TypeCompetition-TR-FRETReactivityHumanRegulatory StatusRUOAssay Time1 hrSample volume10 μLProduct Overview
The Human PD-1 / PD-L2 Inhibitor Screening Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to screen for inhibitors of human PD-1 binding to PD-L2 within one hour. It can also be used as a universal detection tool to identify the ability of human PD-1 to bind to human PD-L2.
Storage
1. Unopened kit should be stored at 2℃-8℃ upon receiving.
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
Materials Provided
IDComponentsSizeFRTP029-C01Human PD-L2 Protein Europium-chelate100 tests/500 testsFRTP029-C02FA Labeled Human PD-1 Protein100 tests/500 testsFRTP029-C03Anti-PD-1 Antibody30 μg/100 tests 150 μg/500 testsDB-04TR-FRET Sample Dilution Buffer, pH7.450 mL/100 tests & 500 testsDB-05TR-FRET Detection Buffer, pH7.450 mL/100 tests & 500 testsAssay Principles
This Human PD-1 / PD-L2 Inhibitor Screening Kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). This assay uses the mixture of biotinylated human PD-L2 and Europium-chelate labeled streptavidin as the Donor and FA Labeled Human PD-1 Protein as the Acceptor.
— When the sample does not contain the inhibitors that block the binding of human PD-1 to human PD-L2, the Donor and Acceptor are in close proximity because of the binding of human PD-1 and human PD-L2. Upon Donor excitation with light of a specific wavelength (337 nm), in addition to Donor emission (620 nm), non-radiative transfer of energy occurs between Donor and Acceptor, resulting in Acceptor emission (665 nm).
— When the sample contains the inhibitors that block the binding of human PD-1 to human PD-L2, the components inhibit the binding between the Donor and Acceptor and thereby prevent FRET from occurring.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
Bioactivity-TR-FRET
Please refer to DS document for the assay protocol.
In this TR-FRET assay, Human PD-L2 Protein Europium-chelate is used as the Donor and FA Labeled Human PD-1 Protein is used as the Acceptor. An inhibition Assay was performed to evaluate the interaction between human PD-1 and human PD-L2 using Anti-PD-1 Antibody resulting in a typical IC50 of 0.7234 nM (QC tested).
The kit is suitable for the detection and characterization of PD-1 / PD-L2 inhibitors. It was shown that the three anti-PD-1 antibodies (Nofazinlimab & Pembrolizumab & Nivolumab) disrupted the interaction, with an IC50 of 0.6622 & 0.8219 & 0.9172 nM. The anti-TNF-alpha antibody (Adalimumab) showed no significant inhibitory effect in the assay as expected. The following data were obtained using the BMG LABTECH CLARIOstar® Plus and are provided for reference only.
Avis des utilisateurs Publier un commentaire
Contact Us
Drug Candidate Licensing
